(accessed 4/23/15)
|
|
- Dorcas Hicks
- 8 years ago
- Views:
Transcription
1 Novel Treatment of Inflammatory Bowel Disease Informed by Science and Patient Choice Unanswered Questions March 11, 2015 Russell D. Cohen, MD, FACG, AGAF Medical marijuana in IBD 1. Unfortunately, with the federal Controlled Substances Act as to Cannabis Sativa, there will be great difficulty in conducting controlled double blind, placebo controlled studies. The efficacy will likely remain anecdota.. 2. I m a Neurologist. My involvement with chronic inflammatory bowel disease patients occurs via their participation in a state-authorized medicinal cannabis program. IBD is one of the very few chronic, severe conditions authorized for this palliative program. MMP is efficacious for palliative, symptomatic therapy in several chronic, neuroinflammatory conditions, including MS, CIDP, and others. The IBD patients report significant palliative effect And the biological umabs you refer to seem to parallel several of the same class agents now available for treating MS, especially the lymphocytic sequestration agents (Dimethyl fumarate, etc.). Reply to both: Controlled clinical trials with cannabis or related substances have not been possible in the past due to federal regulations on the agent. Recent studies presented at medical meetings and published in abstract form have suggested that patients symptoms may improve, but most have failed to date to show objective evidence of disease modification. It is not known what ingredients are necessary, or what mode of delivery, and it very well may vary with individual patients. Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflammatory bowel diseases Mar;20(3): Naftali T, Bar-Lev Schleider L, Dotan I, et al. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebocontrolled study. Clin Gastroenterol Hepatol Oct;11(10): e1.
2 Switching medications 1. Young adult male stable on Humira for several years but wants to switch to more convenient medication doesn t like need for refrigeration travels a lot during the summer, doing a semester abroad in the fall would you offer switch and if so, what would you switch to and how? Reply: It is not suggested that you switch patients from one biological drug to the other for convenience. This was the focus of a clinical trial where many patients who were well flared when the switched drugs. Restarting the previously successful drug may not be successful, as the drug free hiatus will make the patient more likely to develop anti-drug antibodies when restarted. Hoentjen F, Haarhuis BJ, Drenth JP, et al. Elective switching from infliximab to adalimumab in stable Crohn's disease. Inflammatory bowel diseases Mar-Apr;19(4): Please note that there was a recent label change for adalimumab that allows it to be kept at room temperature for up to two weeks. Please read the manufacturer s instructions carefully before proceeding. (accessed 4/23/15) y/o with UC, on humira 2 years, lialda, flare, colonoscopy shows pancolitis. Labs just back antibodies and low drug levels after dose. Pt. s son has Crohn s (19 y/o). Good response for a year to remicade, then flare, anaphylactic Rx. Now on humira - almost 4 years -doing well with humira qoweek and delzicol. 53 y/o has not been on any other treatment with the exception of steroids (currently budesonide). Thoughts for next treatment? Reply patients who form neutralizing antibodies (ie. blood tests positive for antibodies, with little or no drug present) to one biological agent often can be switched to a different biological agent with success. However, they are more prone to develop anti-drug antibodies, so combination therapy of the biological agent with a thiopurine (ie. azathioprine, 6- mercaptopurine) or azathioprine is strongly recommended. In some patients, these traditional therapies may be successful alone, when appropriately dosed.
3 Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximabto-adalimumab switchers with IBD. Inflammatory bowel diseases Oct;20(10): van Schaik T, Maljaars JP, Roopram RK, Verwey MH, Ipenburg N, Hardwick JC, et al. Influence of combination therapy with immune modulators on anti-tnf trough levels and antibodies in patients with IBD. Inflammatory bowel diseases Dec;20(12): Currently, the other FDA-approved biological therapies for ulcerative colitis (other than infliximab and adalimumab) are golimumab and vedolizumab. Gut Microbiome 1. What's the entire hullabaloo about 'fecal transplants" restoring the gut micro biome, and consequently reversing IBD conditions? That's not an assertion, just a question. Reply Hot on the tails of surprisingly good success rates of eradicating relapsing Clostridium difficile in medical patients using a fecal transplant, there has been much speculation that it may be also a potential therapy for Crohn s disease and ulcerative colitis. Studies have shown that there are different types of predominant bacterial strains in many patients with Crohn s and ulcerative colitis, and these or similar strains have been linked to colitis (or more severe colitis ) in mouse models of colitis. So far, the data for fecal transplants have been very disappointing for Crohn s disease (and may make some patients worse), and have been mixed for ulcerative colitis (with the most recent studies negative). Please be aware, that unlike treatment for Clostridium difficile, the use of fecal transplants for other diseases requires the health care provider to obtain FDA approval (an IND). It is not known what other negative factors may be transmitted with the donor stool. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. Journal of Crohn's & colitis Dec 1;8(12): Rossen NG, Fuentes S, van der Spek MJ, Tijssen J, Hartman JH, Duflou A, et al. Findings from a Randomized Controlled Trial of Fecal
4 Transplantation for Patients with Ulcerative Colitis. Gastroenterology Mar 30. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized, Controlled Trial. Gastroenterology Apr 6. Treatment Options Top-Down Treatment 1. I worry that if we adopt this top down treatment theory we will run out of options too early REPLY: smart use of our available therapies should allow you to provide your patients with the best chance of corticosteroid-free response or remission, while sparing them the morbidity that accompanies under-treatment of disease or prolonged steroid-exposure. We current have multiple biological agents for IBD, three immunosuppressants, and likely more therapies in the upcoming years. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet Feb 23;371(9613): Adolescents I see a fair number of adolescents with IBD. Does age impact your treatment algorithm? REPLY: None of us on the panel are pediatric gastroenterologists; I would recommend that you address treatment of children with one of the many fine colleagues who provide excellent care. The older adolescents are often seen in adult GI practices; the care paradigms are the same for these older teens. In fact, many studies suggest that the sooner you start effective therapy with immunomodulators and/or biologics, the more likely the patient is to respond to therapy. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-tosevere Crohn's disease in children. Gastroenterology Mar;132(3):863-73
5 Miyoshi J, Hisamatsu T, Matsuoka K, et al. Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn's disease. Digestion. 2014;90(2): Mild-to-Moderate IBD What about the mild to moderate UC patient, do you start with Mesalamine and still get patients to remission despite that half will go on to have increased disease severity? REPLY: Mesalamine is effective in many patients with mild to moderate ulcerative colitis; if patients go into remission, they are far less likely to relapse if they remain on their mesalamine therapy (ie. indefinitely). Patients who are not well on mesalamine, or who relapse while still on therapy, should be started on additional or alternate therapies. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. The American journal of medicine Jan;114(1): o Race Factors What about the role of race in treatment selection? REPLY: To the best of our knowledge, none of the large studies have shown a convincing difference in treatment response or side-effects based on patient race. Be aware that the vast majority of patients in IBD clinical trials are Caucasian; however, studies in countries with a large proportion of non-caucasians have not yet revealed any red-flags. o Elderly Can anti-tnfs be used in elderly (70 y/o) patient with Parkinson s plus and ostomy? REPLY: Studies in patients older than age 60 have shown that the anti-tnf agents are safe and effective. However, be aware that older patients are more prone to infection with corticosteroids and potentially other therapies that affect the immune system. It is important to limit corticosteroid exposure in this population; more frequent safety monitoring may be advisable.
6 Shung DL, Abraham B, Sellin J, Hou JK. Medical and Surgical Complications of Inflammatory Bowel Disease in the Elderly: A Systematic Review. Digestive diseases and sciences Dec 12. Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, et al. Older age is associated with higher rate of discontinuation of anti-tnf therapy in patients with inflammatory bowel disease. Inflammatory bowel diseases Feb;19(2): o Patients with MS 1. In that regard (the parallelity of use of agents) what is the penetration of use of rituxan and methotrexate in IBD, where those, as well as azathioprine, are used in treating Neuromyelitis Optica and Optic Neuritis, conditions which track and follow MS. 2. I have a female patient with MS and is symptomatic with standard therapy. Where would you go next? REPLY TO BOTH: It is currently advised that patients with multiple sclerosis (MS) not be treated with an anti- TNF agent, due to concerns of possible worsening. Natalizumab is an excellent choice for patients with MS who also have Crohn s disease, as it treats both. Vedolizumab does not have the warnings about MS that the anti-tnfs carry and likely can also be used for Crohn s disease or ulcerative colitis. The immunomodulators most commonly used in IBD patients are azathioprine, 6- mercaptopurine, and methotrexate. Rituximab has not been shown to be effective, to date, in the clinical trials that have been performed in IBD. Leiper K, Martin K, Ellis A, Subramanian S, Watson AJ, Christmas SE, et al. Randomised placebo-controlled trial of rituximab (anti- CD20) in active ulcerative colitis. Gut Nov;60(11): o Pregnancy 1. I have a patient I have treated for years and she is now pregnant. I am treating her with infliximab. Would you change her treatment? REPLY: many experts in IBD preach that the most important part of care of the pregnant patient is to keep their IBD inactive. As a result, in many instances, the IBD medications are not altered in patients who become pregnant. The exceptions are methotrexate and thalidomide, which are both not permitted in pregnancy. Referral for an opinion to an IBD specialist may be
7 desired to get further information regarding medication use during pregnancy, nursing, and preferred mode of delivery. Nielsen OH, Loftus EV, Jr., Jess T. Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review. BMC medicine. 2013;11:174. Schulze H, Esters P, Dignass A. Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation. Alimentary pharmacology & therapeutics Nov;40(9): o Efficacy of Rectal Foam 1. Are you using rectal foam in moderate patients? Any efficacy? REPLY rectally applied therapies (foams, enemas, suppositories) are often very helpful as a sole therapy in some patients with disease limited to the rectum, or as combination therapy in patients with more extensive or resistant disease. Some patients on biologics may still find a benefit with rectally applied therapies. Often these might be needed nightly at first, but then may be given twice a week to help maintain the response. Sandborn WJ, Bosworth B, Zakko S, et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology Apr;148(4): Regueiro M, Loftus EV, Jr., Steinhart AH, Cohen RD. Clinical Guidelines for the Medical Management of Left-Sided Ulcerative Colitis and Ulcerative Proctitis: Summary Statement. Inflammatory bowel diseases Oct;12(10): o Risk of Cancer 1. Can you give me the data on risk of lymphoma in patients with our medicines thiopurines/biologics/azothioprine etc.? REPLY there are multiple studies accessing risk of lymphoma with our current therapies; it is a rare adverse event, and must be taken in perspective with the need to treat patients with effective therapies. There is some data that thiopurines may decrease colorectal cancer risk in IBD colitis; this is by far a more common cancer faced by IBD patients than lymphoma. Exposure to radiation is
8 also linked to lymphoma risk; switching from ionizing radiation to low or no radiation-based imaging (ie. MRI, ultrasound) should also be considered when assessing the lymphoma risk in your patients. Jess T, Lopez A, Andersson M, Beaugerie L, et al. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol Nov;12(11): Lim YJ. Does radiation exposure from abdominal computed tomography increase cancer risk in patients with inflammatory bowel disease and Behcet disease? Gut and liver Jul;8(4): Can you comment on the role of healing mucosa and cancer risk? I have patients ask about this all time. What is the evidence? REPLY: There is a growing body of evidence that healing the mucosa leads to better outcomes in patients with IBD; some recent research suggests that this may extend to lower rates of colorectal cancer, although definitive studies have not been completed to date. Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 2013;11: Discontinuation of Therapy 1. Do you generally stop immunomodulators or biologics in patients when their achieve remission? How do you define remission? REPLY: The clinical trials of available agents have suggested that patients who achieve remission and are then placed on placebo relapse at a much higher rate than those who stay on effective therapy. As a general rule, we continue effective (nonsteroid) therapies in patients with IBD. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):
9 Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut Sep;56(9): Therapeutic Drug Monitoring 1. Therapeutic drug monitoring just makes treatment more costly. Comment? REPLY: There are published studies suggesting the opposite; ie. therapeutic monitoring has been shown to be cost-effective in this setting. Remember that in the case of biologics, due to the high drug cost of each dose, simply avoiding one unnecessary dose or dose escalation by analyzing the trough drug level (and antibodies) easily sets off the cost of the testing. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. The American journal of gastroenterology Oct;100(10): Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol Jun;11(6): Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-tnf treatment: a randomised, controlled trial. Gut Jun;63(6):
11/10/2014. New Treatments in IBD: When, Whom and How. Background. Background. Options. Disease Assessment. What is the evidence?
New Treatments in IBD: When, Whom and How. Background Options Disease Assessment What is the evidence? Kofi Clarke MD, FACP,FRCP (Lond) Clinical Associate Professor, Chief, Gastroenterology, Hepatology
More informationTREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER
Press information for journalists only TREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER Why treat IBD? IBD describes a range of chronic diseases of the gastrointestinal system, encompassing Ulcerative
More informationTop Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms. Stephen B. Hanauer, M.D. University of Chicago
Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms Stephen B. Hanauer, M.D. University of Chicago Treatment Goals c.2008 Induce and maintain response/remission Prevent complications Disease
More informationWhat are the Unmet Needs in the Management of IBD?
23/6/214 What are the Unmet Needs in the Management of IBD? Shane Devlin, MD, FRCPC Inflammatory Bowel Disease Group The University of Calgary Some Real Cases: #1 32 yo male with pan UC. Grumbling phenotype
More informationEvidence of Crohn s Disease. Case Presentation
Witt Wait to Treat tutiled Until Endoscopic Evidence of Crohn s Disease Raymond Cross, MD, MS, AGAF Associate Professor of Medicine Director, IBD Program University of Maryland School of Medicine Co-Director,
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.
More informationEVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze
EVIDENCE BASED TREATMENT OF CROHN S DISEASE Dr E Ndabaneze PLAN 1. Case presentation 2. Topic on Evidence based Treatment of Crohn s disease - Introduction pathology aetiology - Treatment - concept of
More informationOptimizing Treatment Strategies in the Management of Inflammatory Bowel Disease ( IBD )
Inflammatory Bowel Disease Center Optimizing Treatment Strategies in the Management of Inflammatory Bowel Disease ( IBD ) Russell D. Cohen, M.D. F.A.C.G. A.G.A.F. Professor of Medicine, Pritzker Medical
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Multiple Technology Appraisal Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationMedical Therapy for IBD
CHILDREN S DIGESTIVE HEALTH & NUTRITION FOUNDATION NORTH AMERICAN SOCIETY FOR PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION Medical Therapy for IBD I. INTRODUCTION The treatment of Crohn s disease
More informationBriefing Document. Food and Drug Administration. Center for Drug Evaluation and Research
Briefing Document Food and Drug Administration Center for Drug Evaluation and Research Meeting: Joint Meeting of the Gastrointestinal Drugs Advisory Committee (GIDAC) and the Drug Safety and Risk Management
More informationDrug Therapy Guidelines: Humira (adalimumab)
Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:
More informationProbiotics for the Treatment of Adult Gastrointestinal Disorders
Probiotics for the Treatment of Adult Gastrointestinal Disorders Darren M. Brenner, M.D. Division of Gastroenterology Northwestern University, Feinberg School of Medicine Chicago, Illinois What are Probiotics?
More informationDecision systems in quality registries
Decision systems in quality registries Stockholm Dec 9 th, 2014 Jonas Halfvarson, MD, PhD Dept of Gastronterology, Faculty of Medicine and Health, Örebro University 1 Quality registries for chronic diseases
More informationCrohn s and Colitis Center
Crohn s and Colitis Center Dedicated to caring for patients with inflammatory bowel disease Crohn s disease and ulcerative colitis. The Crohn s and Colitis Center is the only center in New England exclusively
More informationHow long will it take to work? You may begin to feel better within a few days or it may take up to six weeks after your first treatment session.
Crohn's and Colitis UK Drug Treatment Information Improving life for people affected by inflammatory bowel diseases Infliximab This information leaflet aims to answer common questions you may have if you
More informationOpportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD
Opportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD Raymond Cross, M.D., M.S., AGAF Associate Professor of Medicine Director of the Inflammatory Bowel Disease Program
More informationUlcerative Colitis & Proctitis. About Ulcerative Colitis & Proctitis
Ulcerative Colitis & Proctitis About Ulcerative Colitis & Proctitis When you first learn that you have ulcerative colitis, you will probably feel overwhelmed. You may not even have heard of ulcerative
More informationCOLORECTAL CANCER SCREENING
COLORECTAL CANCER SCREENING By Douglas K. Rex, M.D., FACG & Suthat Liangpunsakul, M.D. Division of Gastroenterology and Hepatology, Department of Medicine Indiana University School of Medicine Indianapolis,
More informationPHARMACOLOGIC MANAGEMENT FOR INFLAMMATORY BOWEL DISEASE: ULCERATIVE COLITIS & CROHN S DISEASE
PHARMACOLOGIC MANAGEMENT FOR INFLAMMATORY BOWEL DISEASE: ULCERATIVE COLITIS & CROHN S DISEASE Joseph Reilly, B.S., Pharm.D. Residency Program Director / Clinical Specialist AtlantiCare Regional Medical
More informationUnderstanding Colitis and Crohn s Disease
Improving life for people affected by Colitis and Crohn s Disease Understanding Colitis and Crohn s Disease 1 Understanding Colitis and Crohn s Disease Understanding Ulcerative Colitis and Crohn s Disease...
More informationUlcerative Colitis. National Digestive Diseases Information Clearinghouse. What is ulcerative colitis (UC)?
Ulcerative Colitis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is ulcerative colitis (UC)? Ulcerative colitis is
More informationMicroscopic Colitis: Collagenous Colitis and Lymphocytic Colitis
Microscopic Colitis: Collagenous Colitis and Lymphocytic Colitis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is
More informationAdult Inflammatory Bowel Disease Physician Performance Measures Set. August 2011*
Adult Inflammatory Bowel Disease Physician Performance Measures Set August 2011* *Last revised on October 26, 2011 American Gastroenterological Association Adult Inflammatory Bowel Disease Physician Performance
More informationUlcerative colitis patients with low grade dysplasia should undergo frequent surveillance colonoscopies
Ulcerative colitis patients with low grade dysplasia should undergo frequent surveillance colonoscopies David T. Rubin, MD, FACG, AGAF Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationUlcerative Colitis. National Digestive Diseases Information Clearinghouse
Ulcerative Colitis National Digestive Diseases Information Clearinghouse What is ulcerative colitis? Ulcerative colitis is a chronic, or long lasting, disease that causes inflammation irritation or swelling
More informationsubcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Humira (adalimumab subcutaneous injection) Commercial HMO/PPO/CDHP
More informationRheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion
Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationMultiple Sclerosis Step Therapy and Quantity Limit Criteria
Multiple Sclerosis Step Therapy and Quantity Limit Criteria Tysabri (natalizumab) will NOT be included in this step therapy program for Blue Cross and Blue Shield of Illinois because this plan does not
More informationTuesday, July 23, 2013. Karen Hanson, RN, CNP Nurse Practitioner, Division of Gastroenterology and Hepatology Mayo Clinic, Rochester, MN
Tuesday, July 23, 2013 Speakers Karen Hanson, RN, CNP Nurse Practitioner, Division of Gastroenterology and Hepatology Mayo Clinic, Rochester, MN Susanne Benouna Medical Secretary, Division of Gastroenterology
More informationimproving lives through collaborative medicine
improving lives through collaborative medicine ImproveCareNow is a collaborative chronic care network of 77 care centers in 35 states and the District of Columbia and England, where clinicians, researchers,
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationLeukapheresis for inflammatory bowel disease
Issue date: June 2005 Leukapheresis for inflammatory bowel disease Understanding NICE guidance information for people considering the procedure, and for the public Information about NICE Interventional
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
More informationadult services between 1 January and 31 December 2013 had an operation where the
Organisational audit: round 4 Adult services audit tool Section 1: Demographics DEM 1.1 How many IBD patients does your service manage? DEM 1.2 Is this figure: an estimate (enter e ) or from a database/register
More informationIntegrating New Treatments: A Case Based Approach
Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide
More informationOxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients
Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an
More informationUPDATED INVESTOR PRESENTATION June 2015
UPDATED INVESTOR PRESENTATION June 2015 Forward-looking Statements All statements in this presentation other than those of historical fact, including statements regarding our clinical development plans
More informationCrohn s Disease. From research to bedside
Crohn s Disease From research to bedside Primary Care Of The Crohn s Disease Patient Primary Physician s Concerns Vaccination Cancer Cervical Skin Osteoporosis Problems Associated With Vaccinating The
More informationCan Rheumatoid Arthritis treatment ever be stopped?
Can Rheumatoid Arthritis treatment ever be stopped? Robert L. DiGiovanni, DO, FACOI Program Director Largo Medical Center Rheumatology Fellowship robdsimc@tampabay.rr.com Do not pour strange medicines
More informationNew Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence
J a n u a r y 2 0 1 0 w w w. c l i n i c a l a d v a n c e s. c o m V o l u m e 6, I s s u e 1, S u p p l e m e n t 1 New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and
More informationEffective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm
Effective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Tysabri (natalizumab) Policy #: 281 Latest Review Date: October
More informationWhat Is Clostridium Difficile (C. Diff)? CLOSTRIDIUM DIFFICILE (C. DIFF)
What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium, or bug, that can grow in your intestines and cause bad GI symptoms. The main risk
More informationNatalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
More informationINFLAMMATORY BOWEL DISEASE (IBD) MEASURES GROUP OVERVIEW
SPECIFICATION F MEASURES GROUP REPTING ONLY INFLAMMATY BOWEL DISEASE (IBD) MEASURES GROUP OVERVIEW 2012 PHYSICIAN QUALITY REPTING OPTIONS F MEASURES GROUPS: REGISTRY ONLY 2012 PHYSICIAN QUALITY REPTING
More informationComplications that may occur with ulcerative colitis:
Ulcerative Colitis What is ulcerative colitis? Ulcerative colitis is one of the major forms of inflammatory bowel disease. The other major form is Crohn s disease. Ulcerative colitis is felt to be due
More informationhttp://www.ncbi.nlm.nih.gov/pubmedhealth/pmh0001295/?report=printable
of 13 Crohn's disease - PubMed Health PubMed Health. A service of the National Library of Medicine, National Institutes of Health. A.D.A.M. Medical Encyclopedia. Atlanta (GA): A.D.A.M.; 2011. Crohn's disease
More informationArthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis
Arthritis and Rheumatology Clinics of Kansas Patient Education Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis Introduction: For as long as scientists have studied rheumatic disease,
More informationThis fact sheet was adapted from www.cancerinsurancechecklist.org
IBD Insurance Checklist How This Checklist Can Help You The IBD Insurance Checklist is designed to help you compare insurance plans and consider your health needs when shopping for insurance in the Health
More informationI was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several
Track 3: Goals of therapy I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several factors she ll use to decide what s best for me. Let s talk about making treatment
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More informationMultiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report
Multiple Sclerosis in Practice An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and Clinical
More information5.07.09. Aubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)
More informationIssues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation
Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority
More informationLegal Risks and Policy Issues: Inflammatory Bowel Disease
Legal Risks and Policy Issues: Inflammatory Bowel Disease Virginia Mason IBD Course 3/20/15 Lauren D. Feld Mt Sinai School of Medicine Benjamin Byers UW School of Law Andrew D. Feld MD JD Program Chief,
More informationUlcerative colitis: diagnosis and management
Ulcerative colitis: diagnosis and management Word count: 3,367 Abstract word count: 140 Tables and Figures included: 4 1 Abstract Ulcerative colitis is an inflammatory bowel disease that affects approximately
More informationInflammatory Bowel Disease. (Ulcerative Colitis and Crohn s Disease)
Ministry of Defence Synopsis of Causation Inflammatory Bowel Disease (Ulcerative Colitis and Crohn s Disease) Authors: Dr Hazel Younger, Ninewells Hospital and Medical School, Dundee and Dr Craig Mowat,
More informationProposal to Establish the Crohn s and Colitis Center at the University of Miami Miller School of Medicine
Proposal to Establish the Crohn s and Colitis Center at the University of Miami Miller School of Medicine Contents Mission... 1 Background... 2 Services and Programs... 2 Clinical Care... 2 IBD Specialists...
More informationDr Le Dinh Thi Neurology Department
Dr Le Dinh Thi Neurology Department Summary Multiplesclerosis(MS)is considered anautoimmune disease associated with immune activity against central nervous system antigens Immunosuppression and immuno-modulation
More informationEndoscopy is an important diagnostic and therapeutic
ORIGINAL ARTICLE Appropriateness and Diagnostic Yield of Colonoscopy in the Management of Patients with Ulcerative Colitis: A Prospective Study in an Open Access Endoscopy Service Gianpiero Manes, MD,
More informationMedication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010
Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationDigestive and Liver Disease
Digestive and Liver Disease 43 (2011) 1 20 Contents lists available at ScienceDirect Digestive and Liver Disease journal homepage: www.elsevier.com/locate/dld Progress Report The Italian Society of Gastroenterology
More informationClostridium Difficile Colitis. Presented by Mark Skains August 2003
Clostridium Difficile Colitis Presented by Mark Skains August 2003 What is Clostridium Difficile Gram positive rod Produces spores (hang out in diverticula) Forms Endotoxin A + B which cause diarrhea.
More informationWhich injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
More informationPerformance Improvement Strategies in Multiple Sclerosis. Community of Practice Audioconference Recorded December 7, 2010
Performance Improvement Strategies in Multiple Sclerosis Community of Practice Audioconference Recorded December 7, 2010 Audioconference faculty: Bruce A. Cohen, MD Director, Multiple Sclerosis Program
More informationMedical Insurance Long Term (chronic) Conditions Explained
Medical Insurance Long Term (chronic) Conditions Explained October 2013 FS 28452 wpa.org.uk EMS 505226 IS 553152 Introduction This leaflet explains how we manage claims for our policyholders whose medical
More informationAetna Life Insurance Company
Aetna Life Insurance Company Hartford, Connecticut 06156 Amendment Policyholder: Group Policy No.: Effective Date: UNIVERSITY OF PENNSYLVANIA POSTDOCTORAL INSURANCE PLAN GP-861472 This Amendment is effective
More informationMedication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014
Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective
More informationPregnancy and Inflammatory Bowel Disease (IBD)
Oxford University Hospitals NHS Trust Oxford Translational Gastroenterology Unit Pregnancy and Inflammatory Bowel Disease (IBD) page 2 Most women with IBD have a normal pregnancy and deliver a healthy
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationI. Should All New Brunswickers be required to have drug coverage?
Crohn's and Colitis Foundation of Canada Fondation canadlenne des maladies Inflarnmatolres de l'lntestin 600-60 St. Clair Avenue East Toronto, ON Canada M4T INS Tel: (116) 'no.sols Fax: (416) 'n9-0364
More informationRecommendations for Early RA Patients
SUPPLEMENTARY APPENDIX 5: Executive summary of recommendations for patients with early RA, established RA, and high-risk comorbidities Recommendations for Early RA Patients We strongly recommend using
More informationImmune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association
Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell
More informationTYSABRI (NATALIZUMAB)
CLINICAL POLICY TYSABRI (NATALIZUMAB) Policy Number: PHARMACY 154.10 T2 Effective Date: August 1, 2015 Table of Contents CONDITIONS OF COVERAGE... COVERAGE RATIONALE... BENEFIT CONSIDERATIONS... CLINICAL
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationTreating symptoms. An introduction to. Everyone diagnosed with MS can get treatment for their symptoms. The symptoms of MS. Who can get treatment?
Everyone diagnosed with MS can get treatment for their symptoms This resource is an introduction to the treatments that are available. The symbol will point you to further resources. An introduction to
More informationIs Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Monotherapy Treatment of Etanercept
More informationMEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion ACTEMRA (AC-TEM-RA) (tocilizumab) Injection, Solution for Subcutaneous Administration Read this Medication Guide before
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationMultiple Sclerosis Agents Step Therapy with Quantity Limit Program Summary
Multiple Sclerosis Agents Step Therapy with Quantity Limit Program Summary OBJECTIVE The intent of the Multiple Sclerosis (MS) Agents Step Therapy (ST) program is to encourage the use of preferred multiple
More informationBiologic Therapy in Crohn s Disease: The Tricky Tincture of Timing
Biologic Therapy in Crohn s Disease: The Tricky Tincture of Timing Scott, Pharm.D. PGY1 Pharmacy Resident University Health System, San Antonio, TX Division of Pharmacotherapy, The University of Texas
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationLaquinimod Polman, C. et al. Neurology 2005;64:987-991
Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks
More informationGuide to Abdominal or Gastroenterological Surgery Claims
What are the steps towards abdominal surgery? Investigation and Diagnosis It is very important that all necessary tests are undertaken to investigate the patient s symptoms appropriately and an accurate
More informationThe Oxford IBD Service
Gastroenterology Unit, John Radcliffe Hospital The Oxford IBD Service Information for patients Information for patients 1 The Oxford Inflammatory Bowel Disease (IBD) Service Consultant Gastroenterologists
More informationFocus Biobank Inflammatory Bowel Disease
Focus Biobank Inflammatory Bowel Disease University Hospitals Leuven KU Leuven Isabelle Cleynen, PhD Inflammatory Bowel Disease Crohn s disease (CD) Entire GI tract Transmural Fistulas and/or strictures
More informationColon and Rectal Cancer
Colon and Rectal Cancer What is colon or rectal cancer? Colon or rectal cancer is the growth of abnormal cells in your large intestine, which is also called the large bowel. The colon is the last 5 feet
More informationTYSABRI Risk Management Plan. Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc
76 TYSABRI Risk Management Plan Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc 77 Presentation Outline Overview and Goals of Plan Risk Minimization Plan Risk Assessment
More informationCurrent Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists
Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and
More informationAT&T Global Network Client for Windows Product Support Matrix January 29, 2015
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationCrohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals. Sponsored Research Program in Inflammatory Bowel Disease
Crohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals Sponsored Research Program in Inflammatory Bowel Disease Presentation Overview Background on inflammatory bowel disease Partner Overview
More informationBiogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest
Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest Cycle C June 2, 2015 1 Introduction The landscape for the treatment of relapsing Multiple Sclerosis (MS) has quickly evolved over
More information